This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Origin recognition complex subunit 1.
The DNA sequences that define origins of replication haven't been identified yet. ORC is required to assemble the pre-replication complex required to initiate DNA replication.
Human | |
---|---|
Gene Name: | ORC1 |
Uniprot: | Q13415 |
Entrez: | 4998 |
Belongs to: |
---|
ORC1 family |
HS; HSORC1; ORC1Lorigin recognition complex subunit 1; origin recognition complex, subunit 1 (yeast homolog)-like; origin recognition complex, subunit 1 homolog (S. cerevisiae); origin recognition complex, subunit 1 homolog; origin recognition complex, subunit 1; origin recognition complex, subunit 1-like (yeast); origin recognition complex, subunit 1-like; PARC1origin recognition complex 1; Replication control protein 1
Mass (kDA):
97.35 kDA
Human | |
---|---|
Location: | 1p32.3 |
Sequence: | 1; NC_000001.11 (52372829..52404471, complement) |
Nucleus.
Boster biotechnology has been utilized in numerous studies to study the role of the ORC1 marker for the treatment of ORC. Scientists are able to submit their findings in a variety and species and earn credits from Boster for their work. Boster's technology can be utilized by scientists worldwide. Read on to find out more. Below are the Top Uses for the ORC1 marker and what they mean to scientists.
Boster is a world-renowned producer of primary antibodies. Their inventory comprises tens to thousands of different antibodies which include SQSTM1, TARDBP and ABHD5, FGL2 and TLR. These antibodies are frequently employed in research labs and are referenced in thousands upon thousands of scientific research papers. A lot of the primary antibodies created by Boster are also utilized in the research community.
Boster's primary antibodies can be categorized by targets. They include IgA, mAbs and c-myc. Other antibodies are not conjugated, such as the Mouse Anti-Human TRA-1-60 StainAlive? Antibody and the Anti-Human SSEA-4 affinity monoclonal antibody that is purified. These antibodies are frequently employed in cancer research because they can detect a wide range of targets, including HTATIP or BRCA1 proteins.
Dasatinib, an innovative drug, has been shown to be effective in treating this rare and often fatal form of cancer. It works by correcting autophagy-related defects, preventing lipogenesis and apoptosis, and triggering antifibrotic activity. This drug is gaining widespread acceptance for treating patients with orC1 gene-related diseases, including ovarian cancer and lung cancer.
One of the major questions in immunotherapy is whether dasatinib will be effective in treating leukemia. In a recent study, the drug delayed the development of the human FLT3/ITD mutated acute myeloid leukemia in mice following the transplantation human cells. To investigate this, scientists used fluorescence-activated cell sorting immunostaining to analyze the cells.
By inhibiting LIMK1 activity, dasatinib is an excellent treatment for lung cancer. It inhibits lung cancer cell cells' growth, decreases the cofilin p-protein and reduces cell division. These effects, along with the potential for drug reuse suggests that dasatinib is an interesting treatment option for lung cancer. However, further studies are necessary to confirm the benefits of dasatinib in lung cancer.
The study also investigated dasatinib's sensitivity by determining its effect of a synthetic inhibitor on two types of affinity matrices: Kinobeads g and Dasabeads g. The use of these affinity matrices allowed the systematic examination of interactions between proteins and drugs in AGP-01 cell lysates. Dasatinib inhibited 18 Kinases that had apparent dissociation constants of 100 nM.
Another study revealed that dasatinib inhibited cKit D816V mutationant cancer cells. Although the results were positive however, further research is needed to confirm these results in humans. Dasatinib is currently being investigated as an option to treat breast metastasis. Despite the possibility of positive effects, the drug is still being studied in phase I studies.
Researchers used mouse models to test whether dasatinib could slow the growth of tumors in mice. The drug was administered intravenously using gavage, at 30 mg/kg, and the volume of the tumor was measured two times a week. The treatment had a significant effect on the size of the tumor, as evidenced by the reduction in body weight. IHC also examined Ki-67 protein.
Another study looked at whether dasatinib inhibits lung-cancer cell growth through a decrease in the expression of an apoptosis-related marker CD45. It was shown that dasatinib inhibited both lung cancer cell growth and anchorage-independent cell growth. It did not affect the growth of fibroblasts or neoplastics. It was extremely effective against lung cancers. It also inhibited normal cell growth.
P130cas is among the many targets for Dasatinib. Apart from acting as a mechanosensor, it also inhibits focal adhesion, invasion, and migration of cancerous canine mammary cells. The drug also inhibits focal adhesion kinases which mediate cell adhesion.
The drug is highly activity against BCR Abl-expressing cells and has potential in advanced CML and ALL patients. Four out of 29 patients with blast phase or accelerated CML have responded to dasatinib which is a marker for BCR-Abl-mutation. It is safe for use and its positive effects are well-documented. It is important to remember that this is a preclinical study and the clinical efficacy of this drug is still in doubt.
PMID: 7502077 by Gavin K.A., et al. Conserved initiator proteins in eukaryotes.
PMID: 9566895 by Saha P., et al. Human CDC6/Cdc18 associates with Orc1 and cyclin-cdk and is selectively eliminated from the nucleus at the onset of S phase.